Does aspirin change Vascepa (icosapent ethyl) cardiovascular benefit?
Aspirin does not appear to blunt the cardiovascular benefit of Vascepa. In the REDUCE-IT trial, vascepa (icosapent ethyl) reduced major cardiovascular events compared with placebo in patients who were treated with background cardiovascular therapies, which included aspirin for many participants. The benefit was observed across these standard-use therapies rather than being limited to people not taking aspirin [1].
What data support “background aspirin use” in REDUCE-IT?
REDUCE-IT enrolled patients with elevated cardiovascular risk and, in typical practice, many were on antiplatelet therapy. The trial’s reported finding was that icosapent ethyl lowered the risk of the trial’s composite cardiovascular endpoint versus placebo, despite participants receiving common cardiovascular medications such as aspirin [1]. The study design therefore supports that aspirin co-therapy did not negate vascepa’s effect.
Is there a known interaction that reduces effectiveness?
No specific evidence from the provided sources indicates that aspirin reduces vascepa’s cardiovascular efficacy. The available trial-level information points the other way: vascepa improved outcomes on top of routine cardiovascular care, including aspirin [1].
Could aspirin change the side-effect profile when used with Vascepa?
The REDUCE-IT results describe the overall cardiovascular outcome benefit of vascepa on top of standard therapies, including aspirin, but they do not provide an aspirin-specific adjustment to cardiovascular efficacy in the information cited here [1]. If you’re asking about bleeding risk (a common concern when combining antiplatelets with other cardiovascular drugs), that would require looking at safety subgroup details, which are not included in the provided material.
Practical takeaway for patients already taking aspirin
If you’re taking aspirin for cardiovascular prevention, the evidence from REDUCE-IT supports that vascepa’s cardiovascular benefit is achieved even when aspirin is part of background therapy [1].
Sources
- [REDUCE-IT trial results (icosapent ethyl vs placebo) — includes background therapy such as aspirin] https://www.nejm.org/doi/full/10.1056/NEJMoa1812792